100 Years and Counting: Prospects for Defeating Alzheimer's Disease

This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pi...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2006-11, Vol.314 (5800), p.781-784
Main Authors: Roberson, Erik D, Mucke, Lennart
Format: Article
Language:English
Subjects:
Adult and adolescent clinical studies
Alzheimer Disease - pathology
Alzheimer Disease - physiopathology
Alzheimer Disease - therapy
Alzheimer's disease
Alzheimers disease
Amyloid beta-Peptides - immunology
Amyloid beta-Peptides - metabolism
Animals
Biological and medical sciences
Brain
Cholinesterase inhibitors
Clinical trials
Clinical Trials as Topic
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Enzyme Inhibitors - therapeutic use
Enzymes
History of medicine
Humans
Immunization
Immunization, Passive
Medical research
Medical sciences
Medical treatment
Nervous system diseases
Neurology
Neurons
Neuroscience
Nootropic Agents - therapeutic use
Organic mental disorders. Neuropsychology
Peptides
Pharmacology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Reviews
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83
cites cdi_FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83
container_end_page 784
container_issue 5800
container_start_page 781
container_title Science (American Association for the Advancement of Science)
container_volume 314
creator Roberson, Erik D
Mucke, Lennart
description This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pipeline. Among the investigative AD therapies in clinical trials are several strategies to block pathogenic amyloid-β peptides and to rescue vulnerable neurons from degeneration. Complementary but less mature strategies aim to prevent the copathogenic effects of apolipoprotein E and the microtubule-associated protein tau. New insights into selective neuronal vulnerability and the link between aging and AD may provide additional entry points for therapeutic interventions. The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency.
doi_str_mv 10.1126/science.1132813
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3544944</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>20031681</jstor_id><sourcerecordid>20031681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83</originalsourceid><addsrcrecordid>eNqFks1rFDEYxoModls9e1IHQT2NffP1TsaDULZ-QUFBe_AU0vTNdpbZyZrMFPSvN2WHVr3sKYTfbx7CMw9jTzi84VzgcfYdDZ7KRQrD5T224NDquhUg77MFgMTaQKMP2GHOa4DCWvmQHfAGjFDKLNiSA1Q_yKVcueGyWsZpGLth9bb6mmLekh9zFWKqTimQuwHVSf_7iroNpde5Ou0yuUyP2IPg-kyP5_OInX94_335qT778vHz8uSs9mjkWOugPTiUrTIIAYXmWkhqhHBatY0D7zFwUFJqd4FSYWjx0pOmBpwJFIw8Yu92udvpYkOFDWNyvd2mbuPSLxtdZ_8lQ3dlV_HaSq1Uq1QJeDUHpPhzojzaTZc99b0bKE7ZouHQSCP2ilIDapR6ryg4N9DifpGX9wkFsogv_hPXcUpD6bWESRQcRVOk453ky1_KicJtCRzszTDsPAw7D6N88ezv7u78eQlFeDkLLnvXh-QG3-U7zwhEFFi8pztvnceYbrkoW-Olv8Kf73hw0bpVKhnn3wRwCbw8rC2d_QE1N9JD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213621627</pqid></control><display><type>article</type><title>100 Years and Counting: Prospects for Defeating Alzheimer's Disease</title><source>American Association for the Advancement of Science</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Alma/SFX Local Collection</source><creator>Roberson, Erik D ; Mucke, Lennart</creator><creatorcontrib>Roberson, Erik D ; Mucke, Lennart</creatorcontrib><description>This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pipeline. Among the investigative AD therapies in clinical trials are several strategies to block pathogenic amyloid-β peptides and to rescue vulnerable neurons from degeneration. Complementary but less mature strategies aim to prevent the copathogenic effects of apolipoprotein E and the microtubule-associated protein tau. New insights into selective neuronal vulnerability and the link between aging and AD may provide additional entry points for therapeutic interventions. The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency.</description><identifier>ISSN: 0036-8075</identifier><identifier>EISSN: 1095-9203</identifier><identifier>DOI: 10.1126/science.1132813</identifier><identifier>PMID: 17082448</identifier><identifier>CODEN: SCIEAS</identifier><language>eng</language><publisher>Washington, DC: American Association for the Advancement of Science</publisher><subject>Adult and adolescent clinical studies ; Alzheimer Disease - pathology ; Alzheimer Disease - physiopathology ; Alzheimer Disease - therapy ; Alzheimer's disease ; Alzheimers disease ; Amyloid beta-Peptides - immunology ; Amyloid beta-Peptides - metabolism ; Animals ; Biological and medical sciences ; Brain ; Cholinesterase inhibitors ; Clinical trials ; Clinical Trials as Topic ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Enzyme Inhibitors - therapeutic use ; Enzymes ; History of medicine ; Humans ; Immunization ; Immunization, Passive ; Medical research ; Medical sciences ; Medical treatment ; Nervous system diseases ; Neurology ; Neurons ; Neuroscience ; Nootropic Agents - therapeutic use ; Organic mental disorders. Neuropsychology ; Peptides ; Pharmacology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Reviews ; Vaccination</subject><ispartof>Science (American Association for the Advancement of Science), 2006-11, Vol.314 (5800), p.781-784</ispartof><rights>Copyright 2006 American Association for the Advancement of Science</rights><rights>2006 INIST-CNRS</rights><rights>Copyright American Association for the Advancement of Science Nov 3, 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83</citedby><cites>FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/20031681$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/20031681$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,776,780,881,2870,2871,27903,27904,58216,58449</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18266626$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17082448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberson, Erik D</creatorcontrib><creatorcontrib>Mucke, Lennart</creatorcontrib><title>100 Years and Counting: Prospects for Defeating Alzheimer's Disease</title><title>Science (American Association for the Advancement of Science)</title><addtitle>Science</addtitle><description>This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pipeline. Among the investigative AD therapies in clinical trials are several strategies to block pathogenic amyloid-β peptides and to rescue vulnerable neurons from degeneration. Complementary but less mature strategies aim to prevent the copathogenic effects of apolipoprotein E and the microtubule-associated protein tau. New insights into selective neuronal vulnerability and the link between aging and AD may provide additional entry points for therapeutic interventions. The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency.</description><subject>Adult and adolescent clinical studies</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer Disease - physiopathology</subject><subject>Alzheimer Disease - therapy</subject><subject>Alzheimer's disease</subject><subject>Alzheimers disease</subject><subject>Amyloid beta-Peptides - immunology</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Brain</subject><subject>Cholinesterase inhibitors</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Enzymes</subject><subject>History of medicine</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Passive</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Nervous system diseases</subject><subject>Neurology</subject><subject>Neurons</subject><subject>Neuroscience</subject><subject>Nootropic Agents - therapeutic use</subject><subject>Organic mental disorders. Neuropsychology</subject><subject>Peptides</subject><subject>Pharmacology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Reviews</subject><subject>Vaccination</subject><issn>0036-8075</issn><issn>1095-9203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFks1rFDEYxoModls9e1IHQT2NffP1TsaDULZ-QUFBe_AU0vTNdpbZyZrMFPSvN2WHVr3sKYTfbx7CMw9jTzi84VzgcfYdDZ7KRQrD5T224NDquhUg77MFgMTaQKMP2GHOa4DCWvmQHfAGjFDKLNiSA1Q_yKVcueGyWsZpGLth9bb6mmLekh9zFWKqTimQuwHVSf_7iroNpde5Ou0yuUyP2IPg-kyP5_OInX94_335qT778vHz8uSs9mjkWOugPTiUrTIIAYXmWkhqhHBatY0D7zFwUFJqd4FSYWjx0pOmBpwJFIw8Yu92udvpYkOFDWNyvd2mbuPSLxtdZ_8lQ3dlV_HaSq1Uq1QJeDUHpPhzojzaTZc99b0bKE7ZouHQSCP2ilIDapR6ryg4N9DifpGX9wkFsogv_hPXcUpD6bWESRQcRVOk453ky1_KicJtCRzszTDsPAw7D6N88ezv7u78eQlFeDkLLnvXh-QG3-U7zwhEFFi8pztvnceYbrkoW-Olv8Kf73hw0bpVKhnn3wRwCbw8rC2d_QE1N9JD</recordid><startdate>20061103</startdate><enddate>20061103</enddate><creator>Roberson, Erik D</creator><creator>Mucke, Lennart</creator><general>American Association for the Advancement of Science</general><general>The American Association for the Advancement of Science</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QF</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QQ</scope><scope>7QR</scope><scope>7SC</scope><scope>7SE</scope><scope>7SN</scope><scope>7SP</scope><scope>7SR</scope><scope>7SS</scope><scope>7T7</scope><scope>7TA</scope><scope>7TB</scope><scope>7TK</scope><scope>7TM</scope><scope>7U5</scope><scope>7U9</scope><scope>8BQ</scope><scope>8FD</scope><scope>C1K</scope><scope>F28</scope><scope>FR3</scope><scope>H8D</scope><scope>H8G</scope><scope>H94</scope><scope>JG9</scope><scope>JQ2</scope><scope>K9.</scope><scope>KR7</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20061103</creationdate><title>100 Years and Counting: Prospects for Defeating Alzheimer's Disease</title><author>Roberson, Erik D ; Mucke, Lennart</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer Disease - physiopathology</topic><topic>Alzheimer Disease - therapy</topic><topic>Alzheimer's disease</topic><topic>Alzheimers disease</topic><topic>Amyloid beta-Peptides - immunology</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Brain</topic><topic>Cholinesterase inhibitors</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Enzymes</topic><topic>History of medicine</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Passive</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Nervous system diseases</topic><topic>Neurology</topic><topic>Neurons</topic><topic>Neuroscience</topic><topic>Nootropic Agents - therapeutic use</topic><topic>Organic mental disorders. Neuropsychology</topic><topic>Peptides</topic><topic>Pharmacology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Reviews</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberson, Erik D</creatorcontrib><creatorcontrib>Mucke, Lennart</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aluminium Industry Abstracts</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Ceramic Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Computer and Information Systems Abstracts</collection><collection>Corrosion Abstracts</collection><collection>Ecology Abstracts</collection><collection>Electronics &amp; Communications Abstracts</collection><collection>Engineered Materials Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Materials Business File</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>METADEX</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ANTE: Abstracts in New Technology &amp; Engineering</collection><collection>Engineering Research Database</collection><collection>Aerospace Database</collection><collection>Copper Technical Reference Library</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Materials Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Civil Engineering Abstracts</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts – Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Science (American Association for the Advancement of Science)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberson, Erik D</au><au>Mucke, Lennart</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>100 Years and Counting: Prospects for Defeating Alzheimer's Disease</atitle><jtitle>Science (American Association for the Advancement of Science)</jtitle><addtitle>Science</addtitle><date>2006-11-03</date><risdate>2006</risdate><volume>314</volume><issue>5800</issue><spage>781</spage><epage>784</epage><pages>781-784</pages><issn>0036-8075</issn><eissn>1095-9203</eissn><coden>SCIEAS</coden><abstract>This week marks a century since the first description of Alzheimer's disease (AD). Despite approval of several drugs for AD, the disease continues to rob millions of their memories and their lives. Fortunately, many new therapies directly targeting the mechanisms underlying AD are now in the pipeline. Among the investigative AD therapies in clinical trials are several strategies to block pathogenic amyloid-β peptides and to rescue vulnerable neurons from degeneration. Complementary but less mature strategies aim to prevent the copathogenic effects of apolipoprotein E and the microtubule-associated protein tau. New insights into selective neuronal vulnerability and the link between aging and AD may provide additional entry points for therapeutic interventions. The predicted increase in AD cases over the next few decades makes the development of better treatments a matter of utmost importance and urgency.</abstract><cop>Washington, DC</cop><pub>American Association for the Advancement of Science</pub><pmid>17082448</pmid><doi>10.1126/science.1132813</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0036-8075
ispartof Science (American Association for the Advancement of Science), 2006-11, Vol.314 (5800), p.781-784
issn 0036-8075
1095-9203
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3544944
source American Association for the Advancement of Science; JSTOR Archival Journals and Primary Sources Collection; Alma/SFX Local Collection
subjects Adult and adolescent clinical studies
Alzheimer Disease - pathology
Alzheimer Disease - physiopathology
Alzheimer Disease - therapy
Alzheimer's disease
Alzheimers disease
Amyloid beta-Peptides - immunology
Amyloid beta-Peptides - metabolism
Animals
Biological and medical sciences
Brain
Cholinesterase inhibitors
Clinical trials
Clinical Trials as Topic
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Enzyme Inhibitors - therapeutic use
Enzymes
History of medicine
Humans
Immunization
Immunization, Passive
Medical research
Medical sciences
Medical treatment
Nervous system diseases
Neurology
Neurons
Neuroscience
Nootropic Agents - therapeutic use
Organic mental disorders. Neuropsychology
Peptides
Pharmacology
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Reviews
Vaccination
title 100 Years and Counting: Prospects for Defeating Alzheimer's Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A24%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=100%20Years%20and%20Counting:%20Prospects%20for%20Defeating%20Alzheimer's%20Disease&rft.jtitle=Science%20(American%20Association%20for%20the%20Advancement%20of%20Science)&rft.au=Roberson,%20Erik%20D&rft.date=2006-11-03&rft.volume=314&rft.issue=5800&rft.spage=781&rft.epage=784&rft.pages=781-784&rft.issn=0036-8075&rft.eissn=1095-9203&rft.coden=SCIEAS&rft_id=info:doi/10.1126/science.1132813&rft_dat=%3Cjstor_pubme%3E20031681%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c683t-5f5c0a6394860f6251523e722a5497a0cc6f104335ab6346f96dce5e70a8fef83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213621627&rft_id=info:pmid/17082448&rft_jstor_id=20031681&rfr_iscdi=true